Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report details a specific share repurchase transaction executed on February 4, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and capital structure metrics:
- Shares Purchased: 898,126 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,174.5 pence per share; lowest price paid was 1,165.0 pence per share.
- Treasury Holdings: 475,092,284 shares held in Treasury (including unsettled purchases), representing 9.14% of total voting rights.
- Shares in Issue: 5,195,593,373 shares (excluding Treasury shares).
Material Changes
The filing reports a reduction in outstanding shares due to the repurchase of 898,126 shares. Consequently, the total number of shares held in Treasury increased to 475,092,284. The filing does not provide comparative financial data to assess material changes in operating performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary operational note is the Company's intention to hold the repurchased shares in Treasury.
Investor Verification Checklist
- Verify the total cost of the 898,126 shares repurchased based on the weighted average price between 1,165.0 and 1,174.5 pence.
- Confirm the impact of the 9.14% Treasury holding on earnings per share (EPS) calculations.
- Review the remaining authorization for share buybacks under the mandate granted on May 6, 2010.
- Check subsequent filings for the settlement status of the "purchased but not yet settled" shares mentioned in the Treasury count.